Alyeska Investment Group L.P. acquired a new position in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 8,856,844 shares of the company's stock, valued at approximately $9,477,000. Alyeska Investment Group L.P. owned 4.36% of Lucid Diagnostics as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the business. Centiva Capital LP acquired a new position in shares of Lucid Diagnostics during the 3rd quarter valued at $25,000. Cubist Systematic Strategies LLC acquired a new position in shares of Lucid Diagnostics during the first quarter worth about $39,000. Abel Hall LLC purchased a new stake in shares of Lucid Diagnostics in the fourth quarter worth about $33,000. JPMorgan Chase & Co. grew its stake in shares of Lucid Diagnostics by 71,026.1% in the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company's stock valued at $38,000 after buying an additional 32,672 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co raised its holdings in shares of Lucid Diagnostics by 73.2% during the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company's stock valued at $39,000 after buying an additional 14,487 shares during the period. Institutional investors and hedge funds own 74.01% of the company's stock.
Lucid Diagnostics Stock Performance
LUCD opened at $0.98 on Tuesday. The company has a 50-day moving average of $0.99 and a 200-day moving average of $1.11. The company has a market capitalization of $198.89 million, a P/E ratio of -2.08 and a beta of 1.08. Lucid Diagnostics Inc. has a 1-year low of $0.86 and a 1-year high of $1.63.
Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of $1.47 million for the quarter, compared to the consensus estimate of $1.43 million. As a group, sell-side analysts expect that Lucid Diagnostics Inc. will post -0.23 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Wall Street Zen downgraded shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. BTIG Research reissued a "buy" rating and set a $2.50 target price on shares of Lucid Diagnostics in a research report on Monday, August 17th. Weiss Ratings downgraded shares of Lucid Diagnostics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 18th. Ascendiant Capital Markets raised their price target on shares of Lucid Diagnostics from $9.00 to $9.25 and gave the company a "buy" rating in a report on Monday, June 8th. Finally, Maxim Group lowered their price target on shares of Lucid Diagnostics from $3.00 to $2.00 and set a "buy" rating for the company in a report on Friday, May 15th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.19.
View Our Latest Research Report on LUCD
About Lucid Diagnostics
(
Free Report)
Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company's flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid's CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.
Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
